Northwest Biotherapeutics Inc., of Bethesda, a development-stage biotechnology company focused on developing therapies to improve the body’s immune response to cancer, reported a net loss of $67.3 million, or 5.72 per share, in the 12 months ended Dec. 31, 2012, compared to a loss of $32.8 million, or $5.58 per share, for the same period in 2011.
Revenue totaled $772,000 in 2012 versus $10,000 in 2011. (The company did not report results by quarters.) The number of shares outstanding also doubled, accounting for the slight movement in the per-share results.
The company attributed the higher net loss to non-cash accounting charges plus the expenses of setting up clinical trial sites.